Medicinova, Inc.
MNOV Real Time Price USDRecent trades of MNOV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MNOV's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
MNOV Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods to decrease triglyceride synthesis in the liver Mar. 04, 2025
-
Patent Title: Methods of reducing plasma level of macrophage migratory inhibitory factor in patients Feb. 04, 2025
-
Patent Title: Methods of treating post-covid condition(s) Dec. 24, 2024
-
Patent Title: Methods of minimizing cancer metastasis Jul. 23, 2024
-
Patent Title: Methods of preventing cancer metastasis Jun. 11, 2024
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Apr. 02, 2024
-
Patent Title: Methods of treating chemical gas exposure Mar. 12, 2024
-
Patent Title: Ibudilast oral formulations and methods of using same Jan. 09, 2024
-
Patent Title: Methods and dosing regimens using ibudilast and a second agent for cancer therapy Sep. 20, 2022
-
Patent Title: Combination of ibudilast and riluzole and methods of using same Mar. 22, 2022
-
Patent Title: Methods of treating ophthalmic disease/disorder or injury with ibudilast Oct. 26, 2021
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Aug. 10, 2021
-
Patent Title: Combination of ibudilast and interferon-beta and methods of using same Mar. 16, 2021
-
Patent Title: Methods and dosing regimens using ibudilast and a second agent for cancer therapy Aug. 18, 2020
-
Patent Title: Methods of treating glioblastoma multiforme using ibudilast Aug. 27, 2019
-
Patent Title: Combination of ibudilast and riluzole and methods of using same Apr. 16, 2019
-
Patent Title: Method of inhibiting or treating fibrosis Nov. 22, 2016
-
Patent Title: Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels Jun. 07, 2016
-
Patent Title: Method of treating advanced non-alcoholic steatohepatitis May. 24, 2016
-
Patent Title: Treatment of amyotrophic lateral sclerosis (als) with ibudilast Apr. 19, 2016
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Aug. 25, 2015
-
Patent Title: Method of treating liver disorders Feb. 24, 2015
-
Patent Title: Method of treating non-alcoholic fatty liver disease and steatohepatitis Sep. 16, 2014
-
Patent Title: Denibulin di-hydrochloride Jan. 21, 2014
-
Patent Title: Methods and compositions for the treatment of irritable bowel syndrome Aug. 27, 2013
-
Patent Title: Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom Apr. 16, 2013
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Dec. 25, 2012
-
Patent Title: Treatment of progressive neurodegenerative disease with ibudilast Mar. 20, 2012
-
Patent Title: Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods Feb. 21, 2012
-
Patent Title: Phenoxyalkylcarboxylic acid derivatives in the treatment of irritable bowel syndrome Sep. 27, 2011
-
Patent Title: Phenoxyalkycarboxylic acid derivatives in the treatment of ulcerative colitis Aug. 31, 2010
-
Patent Title: Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use Jun. 01, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to MNOV
Recent picks made for MNOV stock on CNBC
ETFs with the largest estimated holdings in MNOV
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MNOV stock a Buy, Sell, or Hold?
- What is the price target for $MNOV stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MNOV stock?
- Who owns the most shares of $MNOV stock?
- What funds own $MNOV stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MNOV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.